Regression of hepatic fibrosis in gamma-irradiated rats by mycophenolate mofetil: potential role of Egr-1

One of the prominent adverse consequences of radiation treatment to the upper right quadrant is hepatic fibrosis. There is an argument that early growth response 1 (Egr-1) manages the hepatic stellate cell activation. Mycophenolate mofetil (MMF), a potent immunosuppressive medication that exhibits potent anti-inflammatory, anti-apoptotic, and antioxidant effects, is frequently prescribed to prevent organ transplant rejection. The purpose of this investigation is to explore the molecular pathways that underpin radiation-induced hepatic fibrosis and to assess the potential influence of MMF on Egr-1 over radiation (IRR)-induced fibrogenesis in rats. MMF (100 mg/kg b.wt. oral) was given to rats exposed to IRR for 4 weeks in a row at a total dose of 12 Gy divided into four doses of 3 Gy each. Assessment of the data demonstrated that MMF administration repressed Egr-1 signaling induced by IRR, diminished oxidative stress, strengthened antioxidant defenses, lessened hepatic inflammatory responses, and suppressed the production of pro-fibrogenic cytokines. Additionally, MMF therapy repaired the histopathological changes brought on by IRR as well as allowed the liver's normal architecture to be restored. In conclusion, the evidence collected revealed that MMF effectively enhanced the architecture of the fibrotic liver and ameliorated the biochemical indicators of liver fibrosis by inhibiting Egr-1.